anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Forty-eight patients diagnosed with symptomatic benign migratory glossitis will be selected from Oral Medicine, Periodontology and Oral Diagnosis department, Faculty of dentistry, Ain shams university. Research ethical committee will review the protocol and the procedure will be explained to the patients and they will sign an informed consent.

Seven days after the diagnosis and selection of patients with (BMG), the atrophic areas will be determined and the patients will attend a control checkup in order to exclude those with constant changing patterns of the red atrophic areas with raised keratotic margins. Only those patients who presented with constant atrophic areas with keratotic margins at the control checkup will be included during the study evaluation process, then the selected patient according the following inclusion and exclusion criteria will be randomly allocated into two groups. Patients met the eligibility criteria will be randomly assigned for 2 different groups using computer generated allocation concealment. Group I: Will include 24 patients with symptomatic BMG receiving Zinc Supplementation once daily and zinc rich diet for one month. (study group).Group II: Will include 24 patients with symptomatic BMG receiving zinc rich diet only For one month. (control group). Intensity of the discomfort will be monitored by the patients using the Visual Analogue Scale (VAS). Saliva will be collected from all included patients to evaluate zinc levels before treatment and one month after treatment only.
BACKGROUND: The aim of this study was to examine the association between different metabolic obesity phenotypes and the non-alcoholic fatty liver disease (NAFLD).
METHODS: This cross-sectional analysis utilized data from the baseline phase of the Ravansar non-communicable diseases (RaNCD) cohort study, which involved 8,360 adults. Participants with a Fatty Liver Index (FLI) score of ≥ 60 was classified as having NAFLD. The FLI score was calculated using liver non-invasive markers and anthropometric measurements. Participants were categorized into four phenotypes based on the presence or absence of metabolic syndrome and obesity. Logistic regression analysis was used to evaluate the association of NAFLD and obesity phenotypes.
RESULTS: According to the FLI index, the prevalence of NAFLD was 39.56%. Participants with FLI scores of ≥ 60 had higher energy intake compared to those in the FLI < 60 group (P = 0.033). In subjects with metabolically unhealthy phenotypes, the level of physical activity was lower compared to those with metabolically healthy phenotypes. The risk of NAFLD in males with the metabolically healthy-obese phenotype increased by 8.92 times (95% CI: 2.20, 15.30), those with the metabolically unhealthy-non-obese phenotype increased by 7.23 times (95% CI: 5.82, 8.99), and those with the metabolically unhealthy-obese phenotype increased by 32.97 times (95% CI: 15.70, 69.22) compared to the metabolically healthy-non-obese phenotype. Similarly, these results were observed in females.
CONCLUSION: This study demonstrated that the risk of NAFLD is higher in individuals with metabolically healthy/obese, metabolically unhealthy/non-obese, and metabolically unhealthy/obese phenotypes compared to those with non-obese/metabolically healthy phenotypes.
Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
The present invention relates generally to adjuvants which comprise a combination of at least two cytokines or functional derivatives thereof. More particularly, the present invention is directed to an adjuvant such as a vaccine adjuvant comprising at least two cytokines or functional derivatives thereof wherein the cytokines are selected from IL-1.beta. and TNP.alpha. or IL-1.beta. and GM-CSF. The present invention is further directed to genetic adjuvants encoding at least two cytokines or derivatives thereof either separately or fused together. The present invention also contemplates a method for enhancing an immune response to an antigen comprising the administration of at least two cytokines which act in synergy to enhance an immune response to said antigen. The present invention is particularly useful m I ' vaccines and genetic vaccine in humans and livestock animals.
This study intends to investigate the experiences of both nurses and patients in the use of a specific brand of such a device known as the 'neospot' device in various sub county, health centres in Kenya. The study also aims at finding out whether the device affects the rate and efficiency of how nurses work in these facilities.

The study will apply a cross sectional design, three facilities will be used as the sampling frame two urban facilities from Nairobi County and one peri urban rural facility from Kajiado county. The participants will be selected randomly. Data will be obtained from a total of 159 randomly selected patients, all the nurses who will be on duty will also be included as participants in the study and the team leaders will be interviewed as key informants for qualitative data. Quantitative data will be analysed using SPSS version 24 for descriptive and inferential statistics, NVIVO software will be used to analyse the qualitative data to determine the themes. Study Duration: Data collection, analysis and report writing will take 4 ½ months.
Available evidence suggests that intensivist management of critically ill patients improves patient outcome, suggesting that greater intensivist coverage might be better still. However, the effects of 24-hour intensivist coverage in ICUs are unknown. In FY11, leadership of the Hospital of the University of Pennsylvania (HUP) decided to roll-out a program for partial night-coverage of the Medical Intensive Care Unit (MICU). In light of this natural experiment, the investigators propose to study the comparative effectiveness of nocturnal intensivist staffing in the HUP Medical Intensive Care Unit. To do so, the investigators propose a randomized clinical trial comparing the presence of a nocturnal intensivist (in-hospital call) to a traditional model of nocturnal coverage with an intensivist available by phone (home call) in the HUP MICU, with respect to patient-centered outcomes and resource utilization. The investigators will randomly assign seven consecutive days (Monday through Sunday) at a time to in-hospital or home call, in two-week blocks. The investigators will conduct primary analyses of all patients admitted during night hours and secondary analyses of various subgroups of patients admitted during night hours as well as all patients admitted during any time of day during the study period from September, 2011, to June, 2011.

A sub-study designed to measure sleep and work duration, sleepiness, and attention in Daytime Intensivists (faculty and fellows) during their medical ICU rotation will be conducted. The variables measured will be compared between periods with and without in-house nocturnal intensivist staffing. All fellows and faculty who rotate through the medical ICU during this study period, Jan 2012 to Dec 2012 will be approached for possible recruitment.
Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
A system and method for ensuring the accuracy of health related information. This system is used for receiving, processing, analyzing, and verifying the accuracy of healthcare data prior to its transmission to a client. Embodiment described may enable patient data, collected from various patient input devices, to be automatically filtered or categorized into one of several categories. The categories are based on the potential accuracy of the data, which are determined by a set of pre-determined rules. Data that surpasses accuracy testing may then be transmitted to a client (hospitals, patient physicians, patient caregivers, patients, etc.) for review and/or incorporation into client records. Data that fails accuracy testing may be discarded.
To understand how upregulated isoglutaminyl cyclase (isoQC) is involved in the initiation of diseases such as cancer, we developed a human KYSE30 carcinoma cell model in which isoQC was stably overexpressed. GO and KEGG analysis of the DEGs (228) and DEPs (254) respectively implicated isoQC on the proliferation invasion and metastasis of cells and suggested that isoQC might participate in the regulation of MAPK, RAS, circadian rhythm, and related pathways. At the functional level, isoQC-overexpressing KYSE30 cells showed enhanced proliferation, migration, and invasion capacity. Next, we decided to study the precise effect of isoQC overexpression on JNK, p-JNK, AKT, p-AKT, ERK, p-ERK, and PER2, as RNA levels of these proteins are significantly correlated with signal levels indicated in RNA-Seq analysis, and these candidates are the top correlated DEPs enriched in RT-qPCR analysis. We saw that only p-ERK expression was inhibited, while PER2 was increased. These phenotypes were inhibited upon exposure to PER2 inhibitor KL044, which allowed for the restoration of p-ERK levels. These data support upregulated isoQC being able to promote cancer cell proliferation and migration in vitro, likely by helping to regulate the MAPK and RAS signaling pathways, and the circadian protein PER2 might be a potential mediator.
The MBRP condition will be based on an existing rolling group treatment manual, which consists of eight 60-minute sessions. Each session will begin with a brief mindfulness practice and a discussion of "what is mindfulness?" and the role mindfulness may play in recovery. The themes are repeated every eight sessions, but in every session the participant is bringing a new direct moment experience to the practices in that session. The groups will also consist of people in various stages of recovery and familiarity with the material, which can make for richer discussions of the material led by the group members themselves. Participants who are randomized to receive rolling MBRP treatment will also have access to the Thrive Recovery smart phone app, which includes audio-guided MBRP meditations for participants to practice in daily life.
The invention relates to a medicament for treating edema of limbs and trunks. The medicament is mainly prepared from the following raw material medicaments in part by weight: 5 to 7 parts of lightyellow sophora root, 1 to 3 parts of figwort root and 1 to 3 parts of root of red-rooted salvia. The invention also discloses application of the medicament for treating the edema of limbs and trunks. The medicament has the advantages that the medicament for treating the edema of limbs and trunks belongs to a Chinese medicinal compound preparation, and the compatibility meets the principle of monarch, minister, assistant and guide of Chinese medicaments. Pharmacodynamic experiments prove that the medicament can obviously reduce lymphedema and venous edema of patients, prevent and treat infection of skin tissues, hyperblastosis of skin and hypoderm and fibrosis complication. The lightyellow sophora root, the figwort root and the root of red-rooted salvia in the medicament for treating the edema of limbs and trunks have obvious synergistic effects. The medicament is suitable for long-term use, and is the safe and effective medicament for treating the edema of limbs and trunks.
PURPOSE: A cosmetic composition containing Brassica oleracea seed extract is provided to suppress melanocyte proliferation and tyrosinase activity. CONSTITUTION: A cosmetic composition for skin whitening contains Brassica oleracea seed extract as an active ingredient. The extract is prepared using water, organic solvent or mixture thereof. The organic solvent includes ethanol, methanol, propylene glycol, butylene glycol, glycerin, hydrous ethanol, hydrous butylenes glycol, hydrous propylene glycol, hexane, or ethyl acetate. The composition further contains arbutin. The composition is manufactured in the form of a skin, skin lotion, skin softener, skin toner, astringent, lotion, nutrition lotion, milk lotion, nutrition cream, massage cream, moisture cream, hand cream, essence, pack, soap, cleansing foam, cleansing lotion, body cleanser, or eye shadow.
New peptide derivs. are water-soluble cpds. of formulae (III) and (IV) and mixt. of these cpds. in a molar ratio of 4:1. In the formulae X is a gp. RCO and Y is H or RCO; or Y is RCO and X is H or RCO; R is 11-19C alkyl or alkenyl; and the amine acids have the configurations Ala:L, Glu:D, Dap:LL. Also new are the parent peptides of formula (III); X, Y=H) and (IV; X, Y=H) and their 4:1 molar mixture. (III) and (IV) are immunological adjuvants which intensify antibody prodn. and influence delayed hypeisensitivity reactions. They are non-arthrogenic, and exists their adjuvant effect (which is greater than that of the parent peptides in aq. soln. or suspension without the need to administer them in oil soln. (III) and (IV) can thus be used as adjuvants for co-admin. with vaccines and in desensitisation against allergens. They can also be used as nonspecific immunostimulants to increase resistance to infections and in antitumour immunotherapy.
A method for delivering a drug comprises administrating a capsule shaped osmotic tablet dosage form comprising the drug that provides drug plasma concentrations that are substantially smoothly ascending over an extended time period. Also described are dosage forms comprising a drug and a pharmaceutically acceptable carrier comprising a capsule shaped tablet core, a semipermeable membrane and an orifice, which releases the drug at an ascending release rate for an extended time period. The capsule shaped tablet core comprises two layers, a first layer comprising a portion of the drug and the second layer comprises a suitable fluid-expanding polymer and is adjacent to the first layer. The semipermeable membrane surrounds the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment. The orifice is formed through the semipermeable membrane and into the capsule shaped tablet core at location adjacent to the first layer to permit the drug to be released from within the compartment into the external fluid environment. Preferably the drug is methylphenidate and can be used in the amount of 100ng to 500mg in manufacture of a medicament for the treatment Attention-Deficit Disorder or Attention Deficit Hyperactivity Disorder to achieve an ascending plasma drug concentration over a time period of 5.5 hours to about 9.5 hours following administration.
PCT No. PCT/EP96/03203 Sec. 371 Date Apr. 23, 1998 Sec. 102(e) Date Apr. 23, 1998 PCT Filed Jul. 19, 1996 PCT Pub. No. WO97/06190 PCT Pub. Date Feb. 20, 1997The present invention relates to a powdery, cross-linked polymer absorbing water and aqueous liquids formed of polymerized, unsaturated, acid groups-containing monomers that are present as salts neutralized to the extent of at least 50 mol-% and which optionally comprise further monomers which are copolymerizable with the acid groups-containing monomers as well as water-soluble polymers, the polymer being formed of acidic, polymerized monomers partially neutralized to the extent of 5-30 mol-%, relative to the acid groups-containing monomer portion. The polymer has a high retention, high liquid absorption under pressure, high swelling pressure, and a low content of soluble components. The present invention further relates to a process for the production of said polymer and to its use as a component in sanitary articles which absorb body fluids and in wound dressings, in current-conducting and light-transmitting cables, as soil conditioners, as a component in packaging materials and in depot materials for the controlled release of active substances.
The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
In this paper we use quantitative and qualitative methods to examine how death investigations in Los Angeles County jails disproportionately naturalize death among Black and Latino incarcerated people. Our study is based on an assessment of 58 autopsies, coroner investigator narratives, and toxicology reports produced between 2009 and 2018. We found that the Medical Examiner frequently arrived at natural or undetermined death determinations that minimized the culpability of carceral staff for loss of life that occurred within county jail. In our dataset, Black people were disproportionately classified as natural. Undetermined deaths were almost exclusively Latino. More than 75% of the cases in our study were deaths that occurred before standing trial. Our findings reveal how biomedical knowledge about incarcerated Black and Latino people is used to erase the life-diminishing effects of punishment, neglect, and maltreatment that are central to the project of mass incarceration.
Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
Risk of tendinitis and tendon rupture is increased. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart or lung transplants. Discontinue if pain or inflammation in a tendon occurs. May exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with a known history of myasthenia gravis. Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose. Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses. Hepatotoxicity: Severe, and sometimes fatal, hepatoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur. Central nervous system effects, including convulsions, anxiety, confusion, depression, and insomnia may occur after the first dose. Use with caution in patients with known or suspected disorders that may predispose them to seizures or lower the seizure threshold Increased. Intracranial pressure (pseudotumor cerebri) has been reported. Clostridium difficile-associated colitis: evaluate if diarrhea occurs. Peripheral neuropathy: discontinue immediately if symptoms occur in order to prevent irreversibility. Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval
Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (12 weeks).
<P>PROBLEM TO BE SOLVED: To provide a skin care preparation for external use, capable of further enhancing wound-healing effects of a silicone of a skin care preparation for external use, and containing the silicone as an essential component.  <P>SOLUTION: This skin care preparation for external use comprises a combination of the latter skin care preparation for external use containing the silicone as the essential component, and a sheet covering the skin care preparation for external use and having a tendency of assuming a negative static voltage. Preferably, the skin care preparation for external use containing the silicone as the essential component is obtained by formulating a silicone material or a solution containing the silicone material as a main component, and a bleaching agent. In another aspect, the skin care preparation for external use containing the silicone as the essential component is obtained by formulating the silicone material or the solution containing the silicone material as a main component, a bleaching agent and an ultraviolet-blocking agent. The sheet having the tendency of assuming the negative static voltage is a silicone sheet or a silicone rubber sheet.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The standard "classic" approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones.
The invention discloses an engineering circRNA for encoding NGF protein, a pharmaceutical composition, a preparation method and application thereof. The engineered circRNA encoding Nerve Growth Factor (NGF) has the advantage of enhancing NGF stability and expression efficiency. By packaging engineered circrnas in nanolipid particles (LNPs), efficient delivery and release of drugs can be achieved. The pharmaceutical composition can be applied by topical administration, gastrointestinal administration, parenteral administration, etc., to provide neuroprotection and treatment of nerve injury. The administration has obvious neuroprotective effect, does not need continuous administration, and avoids the risk of virus infection of animal-derived proteins. One advantage of circRNA-based therapy compared to viral gene delivery is that mRNA is not transported to the nucleus, thereby mitigating the risk of sequence insertion into the genome and thus mutagenesis of cancer.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and design of agents with immunomodulating properties. A new fungal strain Penicillium verrucosum VKPM F-984 and a new immunomodulating agent based on the strain are proposed. The strain is extracted from microflora of ginseng roots and is kept in a medium which contains mineral salts, glucose and asparagine. Fungus mycelium is extracted with a water-alcohol solution (70% ethanol solution). The advantage of this agent is its natural occurrence and effecient stimulation of adaptive capabilities of the body. ^ EFFECT: obtaining an extract which has stimulating action on cell and humoral immunity, improves immune status of the body. ^ 3 cl, 2 ex
Bacterial infections, including Methicillin resistant Staphylococcus aureus (MRSA) infections are a major health problem that has created a pressing need for new antibiotics. Pyridazinone, rhodanine, and pyrazolethione compounds effective inhibit the enzymatic activity of sortase A (srtA) found in gram positive bacteria are disclosed. A structure activity relationship (SAR) analysis led to the identification of several pyridazinone and pyrazolethione analogs that inhibit SrtA with IC50 values in the sub-micromolar range. Compounds that inhibit the S. aureus SrtA sortase may function as potent anti-infective agents as this enzyme attaches virulence factors to the cell wall. Many of these molecules also inhibit the sortase enzyme from B. anthracis suggesting that they may be generalized sortase inhibitors. The novel compounds, compositions, uses, formulations, medicaments, articles of manufacture provide improved materials, uses, and treatments useful in combating infectious disorders.
Subjects will consume 2 sachets with each 7.5 g of dried cubes of chicory root, which equals a total of 12.3 g of dietary fiber per day. Subjects can choose when and how they consume the vegetable product, for example sprinkle it over their meal, or include in existing recipes.